Michel Ducreux

16PUBLICATIONS
105CO-AUTHORS
Molecular targetsPredictive and prognostic markersHaematological tumoursCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (16)

|Feb 03, 2026
Recurrent Resistance Mutations to Lirafugratinib Inform Treatment Sequencing in FGFR2-Driven Tumors.

Francesco Facchinetti, Antoine Hollebecque, Rémy Barbé

|Jan 10, 2026
The Role of Computed Tomography-Determined Total Tumor Volume at Baseline in Predicting Outcomes of Patients with Locally Advanced Unresectable or Metastatic Pancreatic Ductal Adenocarcinoma.

Elissar Moujaes, Jules Dupont, Littisha Lawrance

|Aug 06, 2025
Collagenous colitis in patients treated for cancer: role of immune checkpoint inhibitors. Clinical, histological and immunological features in 15 cases.

Mohamed-Amine Bani, Peggy Dartigues, Ranya Soufan

|May 16, 2025
PRODIGE 29-UCGI 26 (NEOPAN): A Phase III Randomized Trial Comparing Chemotherapy With FOLFIRINOX or Gemcitabine in Locally Advanced Pancreatic Carcinoma.

Michel Ducreux, Romain Desgrippes, Yves Rinaldi

|Oct 26, 2024
KRAS, a New Target for Precision Medicine in Colorectal Cancer?

Alice Boilève, Cristina Smolenschi, Aurélien Lambert

|Aug 01, 2024
Devimistat (CPI-613) With Modified Fluorouarcil, Oxaliplatin, Irinotecan, and Leucovorin (FFX) Versus FFX for Patients With Metastatic Adenocarcinoma of the Pancreas: The Phase III AVENGER 500 Study.

Philip A Philip, Vaibhav Sahai, Nathan Bahary

Pageof 3

Frequent Collaborators

5 joint publications

Antoine Hollebecque

3 joint publications

Alice Boilève

3 joint publications

David Malka

3 joint publications

Thomas Pudlarz